GSK disputes JAMA reports on safety profile of Avandia

Published: 2007-09-14 07:00:00

Updated: 2007-09-14 07:00:00

GlaxoSmithKline said on September 11 that conclusions drawn from the most recent meta-analyses published by Drs. Nissen et. al. and Furberg et. al. in the Journal of the American Medical Association (JAMA) do not confirm a difference in the safety profile of Avandia (rosiglitazone) and Actos (pioglitazone).

According to the company, the Actos analysis, in particular, relied heavily on one tr...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.